title: Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study.
abstract: Incretin based therapies are known to have pleotropic benefits in type 2 diabetes but have not been studied in new onset type 1 diabetes. In this randomized, open label study, we investigated the effect of the addition of exenatide or sitagliptin to insulin in patients with new onset type 1 diabetes. Our data suggest that the addition of exenatide and sitagliptin decreases insulin requirements without increasing endogenous insulin production and hypoglycemic events.
authors.affiliation: Department of Endocrinology, Command Hospital, Lucknow 226002 Uttar Pradesh, India. hariendo@rediffmail.com
authors.forename: K V S
authors.initials: KV
authors.lastname: Hari Kumar
authors.forename: Altamash
authors.initials: A
authors.lastname: Shaikh
authors.forename: Pitambar
authors.initials: P
authors.lastname: Prusty
mesh_terms: D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D006801:Humans; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D010455:Peptides / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*; D000068900:Sitagliptin Phosphate; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*; D014688:Venoms / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D007328:Insulin; D010455:Peptides; D011719:Pyrazines; D014230:Triazoles; D014688:Venoms; D000077270:Exenatide; D000068900:Sitagliptin Phosphate